BIOSOURCE INTERNATIONAL INC
10-Q, EX-27.1, 2000-11-14
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: BIOSOURCE INTERNATIONAL INC, 10-Q, 2000-11-14
Next: BALLENTINE CAPITAL MANAGEMENT INC, 13F-HR, 2000-11-14



<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                           9,227
<SECURITIES>                                         0
<RECEIVABLES>                                    6,624
<ALLOWANCES>                                       239
<INVENTORY>                                      6,752
<CURRENT-ASSETS>                                27,827
<PP&E>                                           9,660
<DEPRECIATION>                                   3,954
<TOTAL-ASSETS>                                  48,781
<CURRENT-LIABILITIES>                            6,937
<BONDS>                                              0
                                0
                                          0
<COMMON>                                            10
<OTHER-SE>                                      41,833
<TOTAL-LIABILITY-AND-EQUITY>                    48,781
<SALES>                                         24,490
<TOTAL-REVENUES>                                24,490
<CGS>                                            9,711
<TOTAL-COSTS>                                   13,660
<OTHER-EXPENSES>                                  (48)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 180
<INCOME-PRETAX>                                    987
<INCOME-TAX>                                        60
<INCOME-CONTINUING>                                928
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                       928
<EPS-BASIC>                                      (.37)
<EPS-DILUTED>                                    (.37)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission